BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Latanoprostene bunod: Phase III started

NicOx disclosed in its 2Q13 earnings that Bausch + Lomb began the open-label, Japanese Phase III JUPITER trial to evaluate once-daily 0.024% latanoprostene bunod for 1 year in about 130 patients...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >